NCT00048945已完成3 期
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 820
- 试验地点
- 74
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of hepatitis B
- •Not pregnant
排除标准
- •Treatment for hepatitis B in past 6 months
- •Other hepatitis infections
- •Severe liver disease
- •Pregnancy
研究者
研究点 (74)
Loading locations...
相似试验
已完成
4 期
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infectionHepatitis C, ChronicNCT00353418Hoffmann-La Roche415
终止
4 期
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.Hepatitis B, ChronicNCT00460850Hoffmann-La Roche60
已完成
4 期
Trial of Pegasys® in Patients With Chronic Hepatitis CChronic Hepatitis CNCT00245414Chugai Pharmaceutical108
已完成
4 期
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.Hepatitis C, ChronicNCT00107653Hoffmann-La Roche569
已完成
4 期
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis BHepatitis B, ChronicNCT00922207Hoffmann-La Roche280